SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Net Income

As of the most recent data (June 2026), BCYPU shows a net income of $-13M. That compares with $-30M in the prior-year period — up 57.8% year over year. That is below the sector sector average of $89M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BCYPU's net income is now $-13M (was $-30M) — a 57.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) is outperforming or lagging.

The its sector sector average net income is about $89M. SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) is at $-13M, which is lower that average. That is roughly 114.4% below the sector mean. Use the comparison chart on this page to see how BCYPU stacks up against individual peers as well.

Tracking BCYPU's net income over time shows whether SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) is scaling, shrinking, or reshaping that part of the business. The current reading is $-13M That compares with $-30M in the prior-year period — up 57.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net income page, Stockcircle has SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-13M) with ownership activity and broader fundamentals.